NCT02154776 - Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 27, 2014

Primary Completion Date

October 26, 2016

Study Completion Date

October 26, 2016

Conditions

Advanced or Metastatic Breast Cancer

Interventions

DRUG

LEE011

3 weeks on and 1 week off

DRUG

Buparlisib

daily

DRUG

Letrozole

2.5 mg daily;

Trial Locations (6)

Novartis Investigative Site, Madrid

Medical University of South Carolina SC, Charleston

Horizon Oncology Center SC, Lafayette

South Texas Accelerated Research Therapeutics SC, San Antonio

University of Utah / Huntsman Cancer Institute SC-3, Salt Lake City

University of California at Los Angeles UCLA SC, Los Angeles